Literature DB >> 4129358

Letter: Serum-complement levels in haemolytic-uraemic syndrome.

B S Kaplan, P D Thomson, G M MacNab.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4129358     DOI： 10.1016/s0140-6736(73)92782-7

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  13 in total

Review 1.  Complement and the Kidney: An Overview.

Authors:  Joshua M Thurman
Journal:  Adv Chronic Kidney Dis       Date:  2020-03       Impact factor: 3.620

2.  Familial, recurrent haemolytic-uraemic syndrome with hypocomplementaemia.

Authors:  J Zachwieja; K Strzykala; W Golda; J Maciejewski
Journal:  Pediatr Nephrol       Date:  1992-03       Impact factor: 3.714

Review 3.  Pathogenesis of the hemolytic uremic syndromes: current concepts.

Authors:  B S Kaplan; V V Vedaranayanan
Journal:  Indian J Pediatr       Date:  1988 Jul-Aug       Impact factor: 1.967

4.  Complement Gene Variants and Shiga Toxin-Producing Escherichia coli-Associated Hemolytic Uremic Syndrome: Retrospective Genetic and Clinical Study.

Authors:  Véronique Frémeaux-Bacchi; Anne-Laure Sellier-Leclerc; Paula Vieira-Martins; Sophie Limou; Theresa Kwon; Annie Lahoche; Robert Novo; Brigitte Llanas; François Nobili; Gwenaëlle Roussey; Mathilde Cailliez; Tim Ulinski; Georges Deschênes; Corinne Alberti; François-Xavier Weill; Patricia Mariani; Chantal Loirat
Journal:  Clin J Am Soc Nephrol       Date:  2019-01-23       Impact factor: 8.237

5.  Recurrent haemolytic-uraemic syndrome with hypocomplementaemia: a case report.

Authors:  R Bogdanović; A Cvorić; V Nikolić; M Sindjić
Journal:  Pediatr Nephrol       Date:  1988-04       Impact factor: 3.714

6.  C3 levels and acute outcomes in Shiga toxin-related hemolytic uremic syndrome.

Authors:  Alejandro Balestracci; Luciana Meni Bataglia; Ismael Toledo; Laura Beaudoin; Caupolican Alvarado
Journal:  Pediatr Nephrol       Date:  2019-09-02       Impact factor: 3.714

7.  Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective study.

Authors:  Lucas Percheron; Raluca Gramada; Stéphanie Tellier; Remi Salomon; Jérôme Harambat; Brigitte Llanas; Marc Fila; Emma Allain-Launay; Anne-Laure Lapeyraque; Valerie Leroy; Anne-Laure Adra; Etienne Bérard; Guylhène Bourdat-Michel; Hassid Chehade; Philippe Eckart; Elodie Merieau; Christine Piètrement; Anne-Laure Sellier-Leclerc; Véronique Frémeaux-Bacchi; Chloe Dimeglio; Arnaud Garnier
Journal:  Pediatr Nephrol       Date:  2018-03-23       Impact factor: 3.714

8.  Activation of the alternative pathway of complement during the acute phase of typical haemolytic uraemic syndrome.

Authors:  J R Ferraris; V Ferraris; A B Acquier; P B Sorroche; M S Saez; A Ginaca; C F Mendez
Journal:  Clin Exp Immunol       Date:  2015-05-05       Impact factor: 4.330

9.  Mannan-binding lectin in children with Escherichia coli O157:H7 haemmorrhagic colitis and haemolytic uraemic syndrome.

Authors:  F Proulx; E Wagner; B Toledano; H Decaluwe; E G Seidman; G-E Rivard
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

Review 10.  STEC-HUS, atypical HUS and TTP are all diseases of complement activation.

Authors:  Marina Noris; Federica Mescia; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2012-09-18       Impact factor: 28.314
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.